Purpose

This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People with kidney failure often require dialysis, which depends on having a reliable arteriovenous fistula (AVF). Traditionally, AVFs are created with surgery, but surgery can involve incisions, longer recovery, and sometimes additional procedures before the AVF can be used. The Velocity System is designed to create an AVF through a small puncture in the skin using a catheter-based approach, without open surgery. This pivotal study will assess how safe the procedure is and how well it works for patients who need dialysis. The study will take place at multiple centers in the United States and will enroll adults with kidney failure who are candidates for fistula creation. Participants will undergo the Velocity procedure and then be followed closely with exams, ultrasounds, and dialysis assessments for up to five years. Taking part is voluntary. Patients may benefit from a less invasive approach to dialysis access, but the main goal is to collect information that could improve future care for people with kidney failure.

Conditions

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. ESRD requiring hemodialysis access or CKD with anticipated need for hemodialysis within 6 months 2. Cubital perforating vein diameter ⩾ 2.0 and ⩽ 5.0 mm 3. Proximal radial artery diameter ⩾ 2.0 and ⩽ 4.0 mm 4. Age > 18 years and < 80 years 5. Willing and competent to give written informed consent 6. Willing and able to complete all study assessments and follow-up requirements

Exclusion Criteria

  1. Study extremity systolic blood pressure < 100mmHg 2. Subjects with occlusion of the ulnar or radial artery at any level or an abnormal Allen's test 3. Subjects with a previous ipsilateral arterio-venous graft or previous ipsilateral upper arm AVF. 4. Distance between Cubital Perforating Vein and Proximal Radial Artery > 3.0 mm 5. Cephalic vein diameter < 2.5 mm at any point from the CPV to the axillary vein 6. Central venous occlusion ipsilateral of the study extremity 7. Severe calcification of the radial artery that significantly impairs ultrasound visualization (e.g., acoustic shadowing) and thus precludes safe or accurate device deployment. 8. Evidence of active systemic infections or localized to the procedure access site within the past 7 days 9. History or evidence of severe cardiac disease (NYHA Functional Class III or IV), myocardial infarction within six months prior to study entry, ventricular tachyarrhythmias requiring continuing treatment, or unstable angina 10. Any contraindication to antiplatelet therapy 11. Currently being treated with another investigational device or drug 12. Known adverse effects to sedation and/or anesthesia which cannot be adequately pre-medicated 13. Uncontrolled or poorly controlled diabetes defined as a HbA1C > 10% 14. Known hypercoagulable condition, bleeding diathesis or coagulation disorder 15. Lymphedema of the study extremity 16. Scheduled kidney transplant within 6 months of enrollment 17. Peripheral white blood cell count < 1,500 cells/μL or > 13,000 cells/μL and neutrophil > 80% 18. Platelet count < 75,000 cells/ μL 19. Current diagnosis of carcinoma (unless in remission > 1 year) 20. Pregnant or currently breast feeding 21. Allergies to nickel or nickel titanium alloy (NiTi) or any of the components of the Velocity Implant or Delivery System 22. Any other medical condition that in the opinion of the investigator would put the welfare of the subject at risk or confound interpretation of the study data 23. Investigator determines that vascular anatomy at intended index procedure site is inappropriate for use of investigational device prior to attempting needle access.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Velocity pAVF System Treatment Arm
Participants in this single-arm, open-label study will undergo creation of a dialysis access using the Velocity Percutaneous Arteriovenous Fistula (pAVF). The Velocity pAVF is designed to create an arteriovenous fistula (AVF) using a minimally invasive, catheter-based procedure through the skin, rather than open surgery. All subjects enrolled will receive the Velocity pAVF procedure. After the procedure, participants will be followed with physical examinations, duplex ultrasound, and dialysis assessments to evaluate fistula maturation, usability for hemodialysis, and long-term function. Additional procedures, if needed to assist maturation or maintain access function, will be recorded. Safety will be monitored throughout the study, including assessment of device-related and procedure-related complications.
  • Device: Velocity Percutaneous Arteriovenous Fistula
    The Velocity pAVF is a catheter-based device used to create an arteriovenous fistula for hemodialysis access through a minimally invasive, percutaneous procedure. Unlike surgical AVF creation or other pAVF systems, Velocity is designed to simplify the procedure and improve consistency of maturation and long-term function. All participants in this study will undergo AVF creation using the Velocity pAVF.
    Other names:
    • Velocity pAVF

Recruiting Locations

Trinity Research Group
Dothan, Alabama 36301

West Coast Kidney Institute Concord
Concord, California 94520
Contact:
Michael Murphy, MD
925-686-1230
michael.murphy@westcoastkidney.com

Apex Research
Riverside, California 92505
Contact:
951-687-6300
dzdawoud@namg.net

Vascular and Embolization Specialists
Cocoa, Florida 32926
Contact:
Laura Dalton
321-321-3001
forms@vascularembo.com

Azura Vascular Care Jacksonville
Jacksonville, Florida 32218
Contact:
Christine Mulligan
717-818-0153
Christine.Mulligan@azuracare.com

Staten Island University Hospital Northwell Health
Staten Island, New York 10305
Contact:
Cindy Lin
718-226-6422
clin14@northwell.edu

Surgical Specialists of Charlotte
Charlotte, North Carolina 28207
Contact:
Jason Burgess, MD
704-333-0741
jburgess@ssclt.com

MUSC Health Orangeburg- Dialysis Access Institute
Orangeburg, South Carolina 29118
Contact:
Virginia Anderson
803-395-3878
andersvi@musc.edu

Advanced Dallas Hospital
Dallas, Texas 75231
Contact:
Neghae Mawla, MD
945-234-7600
mawlamd@gmail.com

Aqua Research
Houston, Texas 77058
Contact:
Rhea Sharma
346-800-1300
rheas@aqua-ri.com

Humble Vascular Surgical Center
Humble, Texas 77338
Contact:
Ruchdi Barakat, MD
346-616-5862
ruchdi.barakat@surgerypartners.com

Fresenius Vascular Care San Antonio
San Antonio, Texas 78207
Contact:
Christine Mulligan
717-818-0153
Christine.Mulligan@azuracare.com

San Antonio Surgical Center
San Antonio, Texas 78216
Contact:
Rajeev Narayan, MD
210-342-2233
rnarayan@sakidney.com

More Details

Status
Recruiting
Sponsor
Venova Medical

Study Contact

Shant Vartanian, MD
408-242-5897
Venos-3@venovamed.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.